Skip to Content
 

News: June, 2019

Expert Q&A: Understanding a new approach to cancer treatment

Saturday, June 29th, 2019

Precision oncology expert Dr. Ben Ho Park sheds light on cancer treatment innovations.

Childhood cancer: how it’s different than for adults

Saturday, June 29th, 2019

The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.

Study identifies critical regulator of tumor-specific T cell differentiation

Saturday, June 29th, 2019

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

Potential probe for early ovarian cancer

Saturday, June 29th, 2019

Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme.

Fish oil and cancer prevention

Saturday, June 29th, 2019

Fish oil supplementation provides a modest but beneficial effect on reducing molecules associated with colorectal cancer development.

Steroid binding to metabolic enzyme

Saturday, June 29th, 2019

Understanding how a steroid-metabolizing enzyme binds to its substrates may aid in designing drugs to treat sexual dysfunction as well as prostate cancer.

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Saturday, June 29th, 2019

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.

Treatment approved for patients with acute graft-versus-host disease

Saturday, June 29th, 2019

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment.

Eng named to GI cancer leadership position at VICC

Saturday, June 29th, 2019

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).

Biomarkers of DNA methylation can be a predictor of breast cancer risk

Saturday, June 29th, 2019

Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk, according to a study published in Journal of the National Cancer Institute.

Next Page »